Xilio Therapeutics, Inc. (XLO)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates
Xilio Therapeutics, Inc. (XLO) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to a loss of $2.52 per share a year ago.
Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?
Xilio Therapeutics (XLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates
Xilio Therapeutics, Inc. (XLO) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.22 per share a year ago.
Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC Transcript
Xilio Therapeutics, Inc. ( XLO ) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC November 10, 2025 4:30 PM EST Company Participants Ruth du Moulin Rene Russo - President, CEO & Director Katarina Luptakova - Chief Medical Officer Christopher Frankenfield - CFO & COO Conference Call Participants Diwakar Davar Aparna Parikh Daina Graybosch - Leerink Partners LLC, Research Division Marc Frahm - TD Cowen, Research Division Presentation Operator Good afternoon, and thank you for joining Xilio Therapeutics conference call and webcast. [Operator Instructions] I would now like to turn the call over to Ruth du Moulin from Xilio Therapeutics.
Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates
Xilio Therapeutics, Inc. (XLO) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.24 per share a year ago.
Xilio Therapeutics, Inc. (XLO) Reports Q4 Loss, Lags Revenue Estimates
Xilio Therapeutics, Inc. (XLO) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.64 per share a year ago.
After Golden Cross, Xilio Therapeutics, Inc. (XLO)'s Technical Outlook is Bright
After reaching an important support level, Xilio Therapeutics, Inc. (XLO) could be a good stock pick from a technical perspective. XLO recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
